MedTrace Logo

Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness

NCT05006833 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21110

Last updated 2025-05-20

No results posted yet for this study

Summary

This study will test the effectiveness of two interventions (parent-targeted text messages and a brief clinician-targeted training) at increasing HPV vaccination among 11- to 12-year-olds living in Florida.

Conditions

Interventions

BEHAVIORAL

Brief Provider Training - Bundled Approach

At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).

BEHAVIORAL

Brief Provider Training - Benefits Approach

At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.

BEHAVIORAL

Parent Interactive Text Message - Bundled Approach

Text messages sent to parents will focus on receiving all three adolescent vaccines.

BEHAVIORAL

Parent Interactive Text Message - Benefits Approach

Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Florida

    lead OTHER

Principal Investigators

  • Stephanie Staras, PhD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-18
Primary Completion
2025-02-25
Completion
2026-03-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05006833 on ClinicalTrials.gov